A new CAR-T cell therapy targeting CD22 has shown promising results in patients with large B-cell lymphoma who failed previous therapies, including CD19-targeted CAR-T treatment. The phase 1 clinical trial at Stanford Medicine found that over 50% of participants, most of whom had relapsed from CD19 therapy, experienced a complete response with durable results. The FDA designated the CD22 therapy as a Breakthrough Therapy. This new approach aims to overcome the limitations of CD19 targeting and offers hope to patients with limited treatment options. Larger trials are ongoing to further evaluate the efficacy of this novel therapy.
Source link
CD22-targeted CAR-T therapy shows promising results in relapsed large B-cell lymphoma
